Sold as Indium In 111 Oxyquinoline. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Indium In-111 Oxyquinoline (sold as Indium In 111 Oxyquinoline), first approved Dec 24, 1985, with 0 new uses approved and 0 published complete response letters.
| Dec 24, 1985 | Indium In 111 OxyquinolineNDA 19044 ยท New molecular entity | Ge Healthcare | 17 | Marketed |
| Jul 25, 2018 | Indium In 111 OxyquinolineANDA 202586 | Bwxt Itg | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA